DLL3 Polyclonal antibody

DLL3 Polyclonal Antibody for WB, IF, IHC, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse

Applications

WB, IF, IHC, ELISA

Conjugate

Unconjugated

Cat no : 25535-1-AP

Synonyms

delta like 3 (Drosophila), Delta like protein 3, Delta3, DLL3, Drosophila Delta homolog 3, SCDO1



Tested Applications

Positive WB detected inmouse brain tissue, mouse liver tissue
Positive IHC detected inhuman liver tissue, mouse brain tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF detected inmouse brain tissue
Planning an IF experiment? We recommend our CoraLite® Plus 647 conjugated versions of this antibody.

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:1000-1:4000
Immunohistochemistry (IHC)IHC : 1:50-1:500
Immunofluorescence (IF)IF : 1:50-1:500
Sample-dependent, check data in validation data gallery

Product Information

25535-1-AP targets DLL3 in WB, IF, IHC, ELISA applications and shows reactivity with human, mouse samples.

Tested Reactivity human, mouse
Cited Reactivityhuman
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen DLL3 fusion protein Ag21965 相同性解析による交差性が予測される生物種
Full Name delta-like 3 (Drosophila)
Calculated molecular weight 65 kDa
Observed molecular weight 65 kDa
GenBank accession numberBC000218
Gene symbol DLL3
Gene ID (NCBI) 10683
RRIDAB_2880122
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

The Delta-Notch pathway is an evolutionarily conserved signaling pathway which controls a broad range of developmental processes including cell fate determination, terminal differentiation and proliferation (PMID: 22353464). In mammals, four Notch receptors (NOTCH1-4) and five activating canonical ligands (JAGGED1, JAGGED2, DLL1, DLL3 and DLL4) have been described (PMID: 22353464). DLL3 is an inhibitory ligand of the Notch signaling pathway that is predominantly localizes to the Golgi apparatus (PMID: 17664336) in normal condition. Normal tissue expression of DLL3 is highest in fetal brain, and DLL3 plays a key role in somitogenesis in the paraxial mesoderm (PMID: 26311731). It has been reported that DLL3 is expressed on the surface of tumor cells of small cell lung cancer (SCLC) and high-grade neuroendocrine carcinomas (LCNEC) and has emerged as a novel therapeutic target (PMID: 26311731; 28487384).

Protocols

Product Specific Protocols
WB protocol for DLL3 antibody 25535-1-APDownload protocol
IHC protocol for DLL3 antibody 25535-1-APDownload protocol
IF protocol for DLL3 antibody 25535-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanIHC

Transl Oncol

High expression of DLL3 is associated with a poor prognosis and immune infiltration in invasive breast cancer patients.

Authors - Chong Yuan
humanIHC

Technol Cancer Res Treat

Investigation of Candidate Genes and Pathways in Basal/TNBC Patients by Integrated Analysis.

Authors - Qi Liu
humanWB

J Immunother Cancer

Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.

Authors - Xin Chen